Merck
  • 主页
  • 查找结果
  • Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Biochemical pharmacology (2013-03-08)
G Cassinelli, C Lanzi, M Tortoreto, D Cominetti, G Petrangolini, E Favini, N Zaffaroni, C Pisano, S Penco, I Vlodavsky, F Zunino
摘要

The activity of heparanase is responsible for heparan sulfate cleavage, thus resulting in the release of heparan sulfate-bound growth factors. Since heparanase activity is upregulated in several tumor types and is implicated in the malignant behavior, the enzyme is regarded as a promising target for antitumor therapy. Based on previous evidence that the heparanase inhibitor SST0001, a non-anticoagulant N-acetylated glycol split heparin, is effective against an Ewing's sarcoma model, the present study was performed to extend the preclinical evaluation of SST0001 to a panel of pediatric sarcoma models, representative of various tumor histotypes (soft tissue and bone sarcomas) and to further elucidate its mode of action. SST0001 treatment downregulated several angiogenic factors in the conditioned media of sarcoma cells, inhibited the pro-invasive effect of heparin-binding factors (VEGF, bFGF, HGF, PDGF), and abrogated PDGF receptor tyrosine phosphorylation. Subcutaneous administration of SST0001 was very effective, resulting in a significant growth inhibition (range, 64-95%) of all tested tumor xenografts. The efficacy of SST0001 was enhanced in combination with antiangiogenic agents (bevacizumab, sunitinib) as documented by the high rate of complete response. The synergistic effect of SST0001 in combination with antiangiogenic agents is consistent with the heparanase mode of action and with the relevant role of heparin-binding proangiogenic/growth factors in the malignant behavior of sarcoma cells.

材料
货号
品牌
产品描述

Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type HP-2, aqueous solution, ≥100,000 units/mL
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于帽贝 (Patella vulgata), Type L-II, lyophilized powder, 1,000,000-3,000,000 units/g solid
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type H-2, aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于大肠杆菌, Type IX-A, lyophilized powder, 1,000,000-5,000,000 units/g protein (30 min assay)
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type H-1, partially purified powder, ≥300,000 units/g solid
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type H-5, lyophilized powder, ≥400,000 units/g solid
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于牛肝脏, Type B-1, ≥1,000,000 units/g solid
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于大肠杆菌, Type VII-A, lyophilized powder, 5,000,000-20,000,000 units/g protein, pH 6.8 (30 min assay)
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于大肠杆菌, ≥10,000,000 units/g protein (30 min assay), recombinant, expressed in E. coli overproducing strain, lyophilized powder
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type HP-2S, aqueous solution, ≥90,000 units/mL
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于大肠杆菌, ≥20,000 units/mg protein, recombinant, expressed in E. coli overproducing strain, lyophilized powder
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于牛肝脏, Type B-3, ≥2,000,000 units/g solid
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type H-3, aqueous solution, ≥90,000 units/mL
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于大肠杆菌, >20,000,000 units/g protein, recombinant, expressed in E. coli, aqueous glycerol solution
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于大肠杆菌, aqueous glycerol solution, ≥5,000,000 units/g protein, pH 6.8 (biuret)
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于罗曼蜗牛, Type H-3AF, aqueous solution, ≥60,000 units/mL
Sigma-Aldrich
β-葡萄糖醛酸酶 来源于散大蜗牛 (花园蜗牛), Type HA-4